{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:45:05Z","timestamp":1783388705273,"version":"3.54.6"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Centre for Clinical Research, Uppsala University"},{"name":"Swedish Breast Cancer Association and the Swedish Cancer Society"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Completion axillary lymph node dissection has been abandoned widely among patients with breast cancer and sentinel lymph node micrometastases, based on evidence from prospective RCTs. Inclusion in these trials has been subject to selection bias, with patients undergoing mastectomy being under-represented. The aim of the SENOMIC (omission of axillary lymph node dissection in SENtinel NOde MICrometases) trial was to confirm the safety of omission of axillary lymph node dissection in patients with breast cancer and sentinel lymph node micrometastases, and including patients undergoing mastectomy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The prospective SENOMIC multicentre cohort trial enrolled patients with breast cancer and sentinel lymph node micrometastases who had breast-conserving surgery or mastectomy at one of 23 Swedish hospitals between October 2013 and March 2017. No completion axillary lymph node dissection was performed. The primary endpoint was event-free survival, with a trial accrual target of 452 patients. Survival proportions were based on Kaplan\u2013Meier survival estimates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The trial included 566 patients. Median follow-up was 38 (range 7\u201367) months. The 3-year event-free survival rate was 96.2 per cent, based on 26 reported breast cancer recurrences, including five isolated axillary recurrences. The unadjusted 3-year event-free survival rate was higher than anticipated, but differed between patients who had mastectomy and those who underwent breast-conserving surgery (93.8 versus 97.8 per cent respectively; P\u2009=\u20090.011). Patients who underwent mastectomy had significantly worse tumour characteristics. On univariable Cox proportional hazards regression analysis, patients who had mastectomy without adjuvant radiotherapy had a significantly higher risk of recurrence than those who underwent breast-conserving surgery (hazard ratio 2.91, 95 per cent c.i. 1.25 to 6.75).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>After 3 years, event-free survival was excellent in patients with breast cancer and sentinel node micrometastases despite omission of axillary lymph node dissection. Long-term follow-up and continued enrolment of patients having mastectomy, especially those not receiving adjuvant radiotherapy, are of utmost importance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjs\/znab141","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T19:53:33Z","timestamp":1618257213000},"page":"1105-1111","source":"Crossref","is-referenced-by-count":23,"title":["Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial"],"prefix":"10.1093","volume":"108","author":[{"given":"Y","family":"Andersson","sequence":"first","affiliation":[{"name":"Department of Surgery, V\u00e4stmanland County Hospital , V\u00e4ster\u00e5s, Sweden"},{"name":"Centre for Clinical Research Uppsala University, V\u00e4stmanland County Hospital , V\u00e4ster\u00e5s, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Bergkvist","sequence":"additional","affiliation":[{"name":"Department of Surgery, V\u00e4stmanland County Hospital , V\u00e4ster\u00e5s, Sweden"},{"name":"Centre for Clinical Research Uppsala University, V\u00e4stmanland County Hospital , V\u00e4ster\u00e5s, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Frisell","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Karolinska University Hospital , Stockholm, Sweden"},{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9518-0902","authenticated-orcid":false,"given":"J","family":"de Boniface","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet , Stockholm, Sweden"},{"name":"Department of Surgery, Capio St G\u00f6ran\u2019s Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"2023063011161729400_znab141-B1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10549-010-1210-7","article-title":"Safety of avoiding routine use of axillary dissection in early stage breast cancer: a systematic review","volume":"125","author":"Pepels","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2023063011161729400_znab141-B2","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"key":"2023063011161729400_znab141-B3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","article-title":"Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial","volume":"14","author":"Galimberti","year":"2013","journal-title":"Lancet Oncol"},{"key":"2023063011161729400_znab141-B4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial","volume":"305","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"key":"2023063011161729400_znab141-B5","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.21873\/invivo.11689","article-title":"Axillary dissection vs. no axillary dissection in breast cancer patients with positive sentinel lymph node: a single institution experience","volume":"33","author":"Arisio","year":"2019","journal-title":"In Vivo"},{"key":"2023063011161729400_znab141-B6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jamcollsurg.2007.08.024","article-title":"Significance of sentinel lymph node micrometastases in human breast cancer","volume":"206","author":"Cox","year":"2008","journal-title":"J Am Coll Surg"},{"key":"2023063011161729400_znab141-B7","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/cncr.22847","article-title":"Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection","volume":"110","author":"Hwang","year":"2007","journal-title":"Cancer"},{"key":"2023063011161729400_znab141-B8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4048\/jbc.2018.21.e44","article-title":"Comparative study between sentinel lymph node biopsy and axillary dissection in patients with one or two lymph node metastases","volume":"21","author":"Lee","year":"2018","journal-title":"J Breast Cancer"},{"key":"2023063011161729400_znab141-B9","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.amjsurg.2018.07.027","article-title":"Survival analysis of early-stage breast cancer patients undergoing axillary lymph node dissection and sentinel lymph node dissection","volume":"216","author":"Nayyar","year":"2018","journal-title":"Am J Surg"},{"key":"2023063011161729400_znab141-B10","first-page":"30","article-title":"Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial","volume":"5","author":"Galimberti","year":"2018","journal-title":"Lancet Oncol"},{"key":"2023063011161729400_znab141-B11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/SLA.0000000000001863","article-title":"Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial","volume":"264","author":"Giuliano","year":"2016","journal-title":"Ann Surg"},{"key":"2023063011161729400_znab141-B12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1245\/s10434-012-2569-y","article-title":"Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048\/13\/2000","volume":"20","author":"Sol\u00e1","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2023063011161729400_znab141-B13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12885-017-3361-y","article-title":"Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial","volume":"17","author":"de Boniface","year":"2017","journal-title":"BMC Cancer"},{"key":"2023063011161729400_znab141-B14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000491704","article-title":"What is the best management of cN0pN1(sn) breast cancer patients?","volume":"13","author":"de Boniface","year":"2018","journal-title":"Breast Care"},{"key":"2023063011161729400_znab141-B15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.adro.2018.03.004","article-title":"Is completion axillary lymph node dissection necessary in patients who are underrepresented in the ACOSOG Z0011 trial?","volume":"3","author":"Gebhardt","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"2023063011161729400_znab141-B16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1503\/cjs.036011","article-title":"CAGS and ACS evidence based reviews in surgery. 40. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis","volume":"55","author":"Latosinsky","year":"2012","journal-title":"Can J Surg"},{"key":"2023063011161729400_znab141-B17","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10549-019-05328-3","article-title":"Do clinical trials truly mirror their target population? An external validity analysis of national register versus trial data from the Swedish prospective SENOMIC trial on sentinel node micrometastases in breast cancer","volume":"177","author":"Andersson","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2023063011161729400_znab141-B18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3322\/caac.21393","article-title":"Breast cancer\u2014major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Giuliano","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2023063011161729400_znab141-B19"},{"key":"2023063011161729400_znab141-B20","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1200\/JCO.2009.24.5001","article-title":"Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes","volume":"28","author":"Andersson","year":"2010","journal-title":"J Clin Oncol"},{"key":"2023063011161729400_znab141-B21","first-page":"31","article-title":"Prediction of non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastases: evaluation of the tenon score","volume":"6","author":"Andersson","year":"2012","journal-title":"Breast Cancer (Auckl)"},{"key":"2023063011161729400_znab141-B22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-004-5781-z","article-title":"An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement","volume":"91","author":"Barranger","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"2023063011161729400_znab141-B23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/COC.0b013e318161dc1b","article-title":"Management of the axilla after the finding of a positive sentinel lymph node: a proposal for an evidence-based risk-adapted algorithm","volume":"31","author":"Evans","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"2023063011161729400_znab141-B24","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ejso.2008.10.003","article-title":"A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis","volume":"35","author":"Houvenaeghel","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"2023063011161729400_znab141-B25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2407-8-66","article-title":"New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients","volume":"8","author":"Kohrt","year":"2008","journal-title":"BMC Cancer"},{"key":"2023063011161729400_znab141-B26","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/bjs.4937","article-title":"Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node","volume":"92","author":"Schrenk","year":"2005","journal-title":"Br J Surg"},{"key":"2023063011161729400_znab141-B27","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1245\/ASO.2003.03.015","article-title":"A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy","volume":"10","author":"Van Zee","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"2023063011161729400_znab141-B28","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.2007.14.4667","article-title":"Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases","volume":"26","author":"Rutgers","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023063011161729400_znab141-B29","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.4155\/fsoa-2018-0008","article-title":"Prognostic significance of further axillary dissection in breast cancer patients with micrometastases & the number of micrometastases: a SEER population-based analysis","volume":"4","author":"Ying-Ying","year":"2018","journal-title":"Future Sci OA"},{"key":"2023063011161729400_znab141-B30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/SLA.0b013e3181f08f32","article-title":"Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial","volume":"252","author":"Giuliano","year":"2010","journal-title":"Ann Surg"},{"key":"2023063011161729400_znab141-B31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/000313481608200124","article-title":"Widespread implications of ACOSOG Z0011: effect on total mastectomy patients","volume":"82","author":"Kenny","year":"2016","journal-title":"Am Surg"},{"key":"2023063011161729400_znab141-B32","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.3390\/cancers12102924","article-title":"External validation of the SERC trial population: comparison with the Multicenter French Cohort, the Swedish and SENOMIC trial populations for breast cancer patients with sentinel node micro-metastasis","volume":"10","author":"Houvenaeghel","year":"2020","journal-title":"Cancers (Basel"},{"key":"2023063011161729400_znab141-B33","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0959-8049(03)00203-X","article-title":"Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines","volume":"39","author":"Cserni","year":"2003","journal-title":"Eur J Cancer"},{"key":"2023063011161729400_znab141-B34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF01807163","article-title":"Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy","volume":"41","author":"Demicheli","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"2023063011161729400_znab141-B35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jso.2930430312","article-title":"Dormancy and breast cancer","volume":"43","author":"Meltzer","year":"1990","journal-title":"J Surg Oncol"},{"key":"2023063011161729400_znab141-B36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-018-4820-0","article-title":"Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes","volume":"171","author":"Andersson","year":"2018","journal-title":"Breast Cancer Res Treat"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/108\/9\/1105\/50745607\/znab141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/108\/9\/1105\/50745607\/znab141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T11:16:49Z","timestamp":1688123809000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/108\/9\/1105\/6278423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5,19]]},"published-print":{"date-parts":[[2021,9,27]]}},"URL":"https:\/\/doi.org\/10.1093\/bjs\/znab141","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,5,19]]}}}